HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Professor Peter Schmid

Prof Schmid is Chair of Cancer Medicine at the prestigious Barts Cancer Institute at Queen Mary University London.  He is also Clinical Director of the Breast Cancer Centre at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. He leads the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre.

Prof Schmid’s specialist cancer interests are breast and lung cancer, cancer immune therapy and early drug development. 

He has successfully led more than 20 national and international academic clinical studies and is a member of several national and international cancer organizations and research groups.  He has authored or co-authored 165 publications and published a book on the management of bone metastases currently in its third edition. 

 
 
 

© Imugene 2018. All rights reserved. ABN 99 009 179 551